A potential cure for the chronic infection of hepatitis C, the liver-destroying disease, was approved by the FDA on Friday. Gilead Sciences Inc.'s Sovaldi, a once-a-day pill, is the first approved to treat hepatitis C without resorting to interferon, an injection that also causes harsh flu-like symptoms. The potential cure doesn't come cheap though: It costs $7,000 a week for 12 weeks. About 3.2 million Americans are affected by hepatitis C and more than 15,000 die from the disease every year, in the form of illnesses such as cirrhosis and liver cancer.
Read it at Reuters
